PUBLISHER: Grand View Research | PRODUCT CODE: 2188629
PUBLISHER: Grand View Research | PRODUCT CODE: 2188629
The global host cell protein (HCP) testing market size was valued at USD 405.1 million in 2025 and is projected to grow from USD 436.7 million in 2026 to USD 804.9 million by 2033, at a CAGR of 9.1% from 2026 to 2033. The market in North America dominated with a revenue share of 44.0% in 2025. The market growth is driven by the increasing development of biopharmaceuticals and biologics, rising demand for monoclonal antibodies and recombinant proteins, and stringent regulatory requirements for host cell protein (HCP) impurity testing to ensure product safety, purity, and quality.
Industry Concentration & Characteristics
The degree of innovation in the HCP testing market is high, driven by advances in sensitive immunoassays, cell-line-specific impurity detection, and automated analytical technologies. For instance, in February 2024, Krishgen Biosystems launched its KRIBIOLISA High Five (H5) HCP ELISA kit, designed to quantify HCP impurities in products manufactured using High Five insect cells. The assay supports in-process and final-product testing, improving impurity monitoring and supporting biopharmaceutical quality control.
The host cell protein (HCP) testing market is witnessing moderate M&A activity, as companies seek to expand specialized analytical testing capabilities. For instance, in June 2025, Fidelio Capital acquired a majority stake in Alphalyse, a contract research organization specializing in liquid chromatography mass spectrometry (LC-MS)-based HCP impurity analysis. The transaction is expected to support Alphalyse's capacity expansion and international growth, strengthening its position in specialized HCP testing services for biopharmaceutical development and manufacturing.
The impact of regulations on the host cell protein (HCP) testing market is significant, as regulatory requirements emphasize the removal and control of HCP impurities during biopharmaceutical manufacturing. Manufacturers must test for residual HCPs to ensure product safety, purity, and quality. These requirements increase demand for reliable HCP testing methods, including ELISA and mass spectrometry, to monitor impurities during production and support quality control of biopharmaceutical products.
The host cell protein (HCP) testing market is witnessing product type expansion through the advances in high-resolution mass spectrometry, sensitive impurity detection, and automated analytical workflows. For instance, in June 2024, Waters Corporation launched the Xevo MRT mass spectrometer, featuring multi-reflecting time-of-flight technology for high-resolution analysis. In addition, in August 2025, Waters demonstrated its use for HCP identification and quantification, detecting 101 host cell proteins in a biotherapeutic sample and supporting sensitive impurity characterization during process development and quality control.
The host cell protein (HCP) testing market is witnessing regional expansion as specialized testing providers strengthen their geographic reach to serve biopharmaceutical manufacturers across key markets. Companies are expanding laboratory capabilities, establishing regional service networks, and improving access to HCP testing technologies, including ELISA and mass spectrometry. These developments help manufacturers access specialized impurity testing services and support HCP characterization, process development, and quality control across biopharmaceutical production.
Global Host Cell Protein (HCP) Testing Market Report Segmentation
This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For the purpose of this report, Grand View Research has segmented the global host cell protein (HCP) testing market on the basis of product & service, technology, application, expression system, end use and region